TOP TEN perturbations for 38462_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38462_at
Selected probe(set): 201304_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38462_at (201304_at) across 6674 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.5178137
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.4930182
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-2.7584114
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

hypoxia study 7 (high altitude) / hypoxia study 7 (sea level)

Relative Expression (log2-ratio):2.4170141
Number of Samples:96 / 98
Experimental hypoxia study 7 (high altitude)
Human peripheral monunuclear blood cells taken from the blood of healthy volunteers after acute elevation to high altitude at the South Pole McMurdo station on the third day.
Control hypoxia study 7 (sea level)
Human peripheral monunuclear blood cells taken from the blood of healthy volunteers at sea level at the South Pole McMurdo station on the third day.

interferon-alpha-kinoid study 2 (240ug; 168d) / placebo treated whole blood sample

Relative Expression (log2-ratio):-2.3988905
Number of Samples:3 / 6
Experimental interferon-alpha-kinoid study 2 (240ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 4 doses of 240ug INK-K at day 0, 7, 58 and 84. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control placebo treated whole blood sample
Whole blood samples of patients with systemic lupus erythematosus after treatment with placebo (0.9% NaCl; hemocyanin as carrier). Patients had 3 doses at day 0, 7 and 58. Sample was taken 168 days after the first application of TNF-K.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.3952122
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

attention deficit hyperactivity disorder (ADHD) study 1 / normal blood sample

Relative Expression (log2-ratio):2.3272247
Number of Samples:2 / 24
Experimental attention deficit hyperactivity disorder (ADHD) study 1
Blood samples from generally healthy children ( age > 24 month) with attention deficit hyperactivity disorder (ADHD). Patients undergone diagnostic assessment, using DSMIV-TR criteria - ADOS and ADI-R, and comprehensive clinical testing (cognitive testing, language measures, medical history, height and weight, head circumference, and behavioral questionnaires).
Control normal blood sample
Blood samples from generally healthy children, which were followed in an endocrine clinic due to idiopathic short stature and constitutional delay of growth. Only children with no abnormal findings were enrolled in the study. Children diagnosed with intellectual disability or any neurological disorder were excluded.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.2840357
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.095868
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-2.0901823
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer┬┤s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.